A citation-based method for searching scientific literature

Gwenaëlle Le Pen, James Kew, Daniela Alberati, Edilio Borroni, Marie Paule Heitz, Jean-Luc Moreau. Biol Psychiatry 2003
Times Cited: 92







List of co-cited articles
1461 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Ronan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Annick Coste, Christophe Lanneau, Christophe Desvignes, Martine Poncelet, Michel Heaulme, Vincent Santucci, Michel Decobert,[...]. Neuropsychopharmacology 2005
178
43

The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
Gene G Kinney, Cyrille Sur, Maryann Burno, Pierre J Mallorga, Jacinta B Williams, David J Figueroa, Marion Wittmann, Wei Lemaire, P Jeffrey Conn. J Neurosci 2003
144
39

The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study.
Laszlo G Harsing, Istvan Gacsalyi, Geza Szabo, Eva Schmidt, Nora Sziray, Claude Sebban, Brigitte Tesolin-Decros, Peter Matyus, Andras Egyed, Michael Spedding,[...]. Pharmacol Biochem Behav 2003
88
37

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
34

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
259
33

Modulation of N-methyl-D-aspartate receptor function by glycine transport.
R Bergeron, T M Meyer, J T Coyle, R W Greene. Proc Natl Acad Sci U S A 1998
341
31






ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter.
B N Atkinson, S C Bell, M De Vivo, L R Kowalski, S M Lechner, V I Ognyanov, C S Tham, C Tsai, J Jia, D Ashton,[...]. Mol Pharmacol 2001
147
26

D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
505
26

Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels.
Marzia Martina, Yelena Gorfinkel, Samantha Halman, John A Lowe, Pranav Periyalwar, Christopher J Schmidt, Richard Bergeron. J Physiol 2004
136
26

Gene knockout of glycine transporter 1: characterization of the behavioral phenotype.
Guochuan Tsai, Rebecca J Ralph-Williams, Marzia Martina, Richard Bergeron, Joanne Berger-Sweeney, Kevin S Dunham, Zhichun Jiang, S Barak Caine, Joseph T Coyle. Proc Natl Acad Sci U S A 2004
158
26

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Hsien-Yuan Lane, Yue-Cune Chang, Yi-Ching Liu, Chih-Chiang Chiu, Guochuan E Tsai. Arch Gen Psychiatry 2005
209
26



Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, G Silipo, M Lichtenstein. Arch Gen Psychiatry 1999
356
22

To model a psychiatric disorder in animals: schizophrenia as a reality test.
B K Lipska, D R Weinberger. Neuropsychopharmacology 2000
480
22

Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain.
Beatriz Cubelos, Cecilio Giménez, Francisco Zafra. Cereb Cortex 2005
224
22

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
Denis Boulay, Philippe Pichat, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Jean Paul Terranova, Nancy Rogacki, Jeanne Stemmelin, Annick Coste, Christophe Lanneau, Christophe Desvignes,[...]. Pharmacol Biochem Behav 2008
73
28


Discovery and SAR of org 24598-a selective glycine uptake inhibitor.
A Brown, I Carlyle, J Clark, W Hamilton, S Gibson, G McGarry, S McEachen, D Rae, S Thorn, G Walker. Bioorg Med Chem Lett 2001
78
24

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Pesah Lichtenberg, Gali Bar, Daniel C Javitt. Biol Psychiatry 2004
173
20


Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.
Benjamin K Yee, Ela Balic, Philipp Singer, Cornelia Schwerdel, Thomas Grampp, Laetitia Gabernet, Irene Knuesel, Dietmar Benke, Joram Feldon, Hanns Mohler,[...]. J Neurosci 2006
115
20

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
Kenneth W Perry, Julie F Falcone, Matthew J Fell, John W Ryder, Hong Yu, Patrick L Love, Jason Katner, Kimberly D Gordon, Mark R Wade, Teresa Man,[...]. Neuropharmacology 2008
71
26

Glycine transporters are differentially expressed among CNS cells.
F Zafra, C Aragón, L Olivares, N C Danbolt, C Giménez, J Storm-Mathisen. J Neurosci 1995
428
19

Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors.
K E Smith, L A Borden, P R Hartig, T Branchek, R L Weinshank. Neuron 1992
390
19


Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition.
Jesús Gomeza, Swen Hülsmann, Koji Ohno, Volker Eulenburg, Katalin Szöke, Diethelm Richter, Heinrich Betz. Neuron 2003
238
18



Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
18



Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine.
B K Lipska, N R Swerdlow, M A Geyer, G E Jaskiw, D L Braff, D R Weinberger. Psychopharmacology (Berl) 1995
293
17

Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia.
R A Chambers, J Moore, J P McEvoy, E D Levin. Neuropsychopharmacology 1996
153
17

Amelioration of negative symptoms in schizophrenia by glycine.
D C Javitt, I Zylberman, S R Zukin, U Heresco-Levy, J P Lindenmayer. Am J Psychiatry 1994
286
16

Adjunctive high-dose glycine in the treatment of schizophrenia.
D C Javitt, G Silipo, A Cienfuegos, A M Shelley, N Bark, M Park, J P Lindenmayer, R Suckow, S R Zukin. Int J Neuropsychopharmacol 2001
122
16

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.
Mark D Black, Geoffrey B Varty, Michal Arad, Segev Barak, Amaya De Levie, Denis Boulay, Philippe Pichat, Guy Griebel, Ina Weiner. Psychopharmacology (Berl) 2009
68
22

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
D C Goff, G Tsai, J Levitt, E Amico, D Manoach, D A Schoenfeld, D L Hayden, R McCarley, J T Coyle. Arch Gen Psychiatry 1999
308
15

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
267
15



Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).
Denise Manahan-Vaughan, Verena Wildförster, Christian Thomsen. Eur J Neurosci 2008
51
27

NMDA receptor hypofunction model of schizophrenia.
J W Olney, J W Newcomer, N B Farber. J Psychiatr Res 1999
708
14


Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
Kenji Hashimoto, Takeshi Fukushima, Eiji Shimizu, Naoya Komatsu, Hiroyuki Watanabe, Naoyuki Shinoda, Michiko Nakazato, Chikara Kumakiri, Shin-ichi Okada, Hisanori Hasegawa,[...]. Arch Gen Psychiatry 2003
381
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.